Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results

HOLON, Israel, Feb. 9, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the fourth quarter and year ended December 31, 2015.

Anat Cohen-Dayag, Ph.D., Compugen's President and Chief Executive Officer, stated, "This past year was a year of significant accomplishment for our company with respect to our unique discovery infrastructure and our target pipeline program.  Important to both was the demonstration of functional activity in preclinical models of cancer immunotherapy for an immune checkpoint antibody program for which the target had been predicted entirely in silico by Compugen. In addition to generating a compelling antibody drug program, this achievement provides a key demonstration of the predictive power of Compugen's discovery capabilities."

Dr. Cohen-Dayag continued, "Another key achievement was the aggressive advancement of a second immune checkpoint program, CGEN-15029, which is our leading internal immuno-oncology program. For this program, initiated only last year, we already have identified functional antibodies from which we will select our therapeutic clinical candidate. Outside of our immuno-oncology core focus, important progress was achieved during the year involving our ADC activities, in particular with our lead ADC program, CGEN-15027, and with our autoimmune product candidate, CGEN-15001."

Dr. Cohen-Dayag concluded, "Looking ahead, with substantially expanded capabilities and capacity, during 2016 our R&D focus will be on the advancement of these programs, the addition of immuno-oncology programs based on targets now undergoing validation, and further target discovery efforts."

Revenues for the fourth quarter of 2015 were $8.3 million, compared with $6.6 million in the comparable period of 2014. The increase in revenues is attributed to achievement of the third milestone in the amount of $7.8 million in 2015, compared with $6.0 million in the comparable period of 2014, relating to the August 2013 collaboration and license agreement with Bayer Healthcare (the "Bayer agreement").   Revenues for the year ended December 31, 2015 were $9.3 million, compared with $12.4 million in the comparable period of 2014. The decrease in revenues is attributable to the relevant portions of the non-refundable upfront payment relating to the Bayer agreement.

R&D expenses for the fourth quarter and year ended December 31, 2015 were $5.8 million and $21.2 million, respectively, compared with $4.8 million and $15.1 million in the comparable periods in 2014. The increase in both cases primarily reflects a substantial increase in the activities involving our pipeline program candidates, including the hiring of additional professional employees and advisors to support pre-clinical activities as well as the full impact of the move to new facilities in South San Francisco which occurred in mid-2014.

Net loss for the fourth quarter of 2015 was $0.5 million, or $0.01 per diluted share, compared with a net loss of $1.5 million, or $0.03 per diluted share, in the comparable period of 2014. Net loss for the year ended December 31, 2015 was $20.2 million, or $0.40 per diluted share, compared with a net loss of $11.1 million, or $0.26 per diluted share, in the same period of 2014.

As of December 31, 2015, cash, cash related accounts, short-term and long-term bank deposits totaled $81.4 million, compared with $108.4 million at December 31, 2014. Cash balances for December 31, 2015 do not include the expected payment from Bayer HealthCare in connection with the third milestone of $7.8 million, which will be remitted during the first quarter of 2016.  The Company has no debt.

Conference Call and Webcast Information 
Compugen will hold a conference call to discuss its fourth quarter and yearend 2015 results today, February 9, 2016, at 10:00 a.m. ET. To access the conference call, please dial 1-888-668-9141 from the US, or +972-3-918-0609 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-326-9310 from the US or +972-3-925-6925 internationally. The replay will be available through February 11, 2016.

About Compugen
Compugen is a leading drug discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The Company's current pipeline primary focus is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel targets and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Holon, Israel, with R&D facilities in Holon and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Forward-Looking Statement 
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and may not be successful in generating revenues, and the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Company contact: 
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd. 
Email: [email protected] 
Tel: +972-52-598-9892

SOURCE Compugen Ltd.

Related Links

http://www.cgen.com